Germany’s Merck KGaA announced an $11.3 billion agreement to acquire U.S.-based life-sciences supplier Bio-Techne. This move marks the company’s most significant expansion since the $17 billion Sigma-Aldrich acquisition over a decade ago. The strategy signals a shift under new CEO Kai Beckmann, who aims to aggressively scale the firm’s laboratory tools division.
Simultaneously, the tech investment firm Prosus deepened its commitment to digital health by backing the French insurer Alan. The deal values the AI-powered healthcare platform at $6.25 billion, highlighting a growing institutional appetite for tech-integrated medical services. These moves collectively pushed healthcare stocks to the top of the daily gainers list as market participants pivoted toward defensive assets.
Comments (0)
No comments yet. Be the first!